5 results
The primary objective is to determine the effect of locally administered rhAPC on LPS-induced lung inflammation and coagulation. By using measurements on cells harvested from bronchoalveolar lavage (BAL)-fluid and in BAL-fluid supernatants, we will…
To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock compared with placebo.
Primary objective: To determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous…
The primary objective is to determine the effect of intravenously administered rhAPC on HDM-LPS induced allergic lung inflammation.
The Primary Objectives for the study are:* Demonstrate the non-inferiority (NI) of lefamulin versus comparator with respect to the Early Clinical Response (96 ± 24 hours after the first dose of study drug) in the Intent to Treat (ITT) Analysis Set (…